178 related articles for article (PubMed ID: 35785754)
1. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.
Blayney DW; Schwartzberg L
Cancer Treat Rev; 2022 Sep; 109():102427. PubMed ID: 35785754
[No Abstract] [Full Text] [Related]
2. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Schwartzberg LS; Bhat G; Peguero J; Agajanian R; Bharadwaj JS; Restrepo A; Hlalah O; Mehmi I; Chawla S; Hasal SJ; Yang Z; Cobb PW
Oncologist; 2020 Aug; 25(8):e1233-e1241. PubMed ID: 32476162
[TBL] [Abstract][Full Text] [Related]
3. Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA; Greene D; Lakshmikanthan S; Kolli P; Chawla S; Lebel F
J Clin Pharmacol; 2021 Feb; 61(2):204-210. PubMed ID: 32827162
[TBL] [Abstract][Full Text] [Related]
4. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
Carrato A; Guillén-Ponce C; Grande-Pulido E
Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
6. Agents under investigation for the treatment and prevention of neutropenia.
Huston A; Lyman GH
Expert Opin Investig Drugs; 2007 Nov; 16(11):1831-40. PubMed ID: 17970641
[TBL] [Abstract][Full Text] [Related]
7. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
8. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
Esser M; Brunner H
Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer.
Kotake T; Miki T; Akaza H; Kubota Y; Nishio Y; Matsumura Y; Ota K; Ogawa N
Cancer Chemother Pharmacol; 1991; 27(4):253-7. PubMed ID: 1705488
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
13. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
[TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma.
Gebbia V; Testa A; Valenza R; Borsellino N; Cipolla C; Cannata G; Curto G; Latteri M; Florena M; Gebbia N
J Chemother; 1993 Jun; 5(3):186-90. PubMed ID: 7690396
[TBL] [Abstract][Full Text] [Related]
15. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
16. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
Gómez Raposo C; Pinto Marín A; González Barón M
Clin Transl Oncol; 2006 Oct; 8(10):729-34. PubMed ID: 17074671
[TBL] [Abstract][Full Text] [Related]
17. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Aapro M; Crawford J; Kamioner D
Support Care Cancer; 2010 May; 18(5):529-41. PubMed ID: 20191292
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
[TBL] [Abstract][Full Text] [Related]
20. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
